Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00039299 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Treating Patients With Prostate Cancer
A Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00039299: Completed Phase 1 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00039299 is a Phase 1 study that has completed, run by Jonsson Comprehensive Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00039299, a Phase 1 study, has completed, sponsored by Jonsson Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of T-cell therapy in treating patients who have prostate cancer that has not responded to hormone therapy.
Interventions
- BIOLOGICAL therapeutic autologous lymphocytes
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-03 |
| Est. Completion | 2003-06 |
| Phase | Phase 1 |
What the finished NCT00039299 record still lists
NCT00039299 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which therapeutic autologous lymphocytes is the first listed.
NCT00039299 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00039299 about?
NCT00039299 is a clinical study titled "Biological Therapy in Treating Patients With Prostate Cancer". RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Treating a person's T cells in the laboratory and then reinfusing them may cause a stronger immune response and kill more tumor cells. PURPOSE: Phase I trial to study the effectivene...
What is the current status of trial NCT00039299?
This trial is currently completed. It is a Phase 1 study. The study started on 2002-03. Estimated completion is 2003-06.
What interventions are being tested in trial NCT00039299?
The interventions under investigation include: therapeutic autologous lymphocytes (BIOLOGICAL).
Who is sponsoring clinical trial NCT00039299?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia